DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Human Growth Hormone (HGH) - Market Outlook 2022" report to their offering.
In the report, human growth hormone market assessment is done across major markets such as Europe, The US and Japan. The US is the world's largest HGH market accounting for more than one-third of global HGH market value. In-depth analysis of HGH therapy in aforementioned regions is done on the basis of overall HGH market value as well as pediatric HGH market.
Global human growth hormone therapy industry is highly consolidated with three major players - Novo Nordisk, Pfizer and Eli Lilly and Company dominating the market. These industry players as well as other leading players such as Merck KGaA and Roche are profiled herein based on attributes such as business overview, product segments, financial and business strategies.
The report also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global HGH therapy market.
Global HGH Market Dynamics
Industry Trends & Developmens
- Advent of Long-acting rhGH
- Use of HGH as Performance Enhancers
- Products Under Development
- Prevalence of Pituitary Dysfunction
- Low Market Penetration
- Growing Geriatric Population
- Rising Healthcare Expenditure and Affordability
- High Treatment Cost
- Adverse Side-effects of rhGH
- Illicit Uses of HGH
- Reimbursement Issues for Patients
- Poor Adherence to Therapy by Patient
- Stringent Regulatory Approvals
- Merck Serono
- Novo Nordisk
- Eli Lilly
- F. Hoffmann-La Roche Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/k6nk6p/global_human